SCHEMBL17015337

SCHEMBL17015337

c1ccc(-n2ccc3ccc4c5ccccc5n(-c5ccc6c(ccc7ccccc76)c5)c4c32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
BIRC5 O15392 1/20 0.36
ALDH1A1 P00352 4/20 0.34
HSD17B10 Q99714 2/20 0.34
CYP1B1 Q16678 2/20 0.34
HIF1A Q16665 1/20 0.34
HPRT1 P00492 1/20 0.33
HPGD P15428 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CYP1A2 P05177 2/20 0.31
PGR P06401 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
CYP2A6 P11509 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
TERT O14746 1/20 0.31
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016210 0.95 KDM4E (0.42) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL16357325 0.94 KDM4E (0.40) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL17015344 0.92 KDM4E (0.39) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL17016211 0.90 KDM4E (0.39) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL17015335 0.90 KDM4E (0.39) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL17015328 0.90 KDM4E (0.41) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL15632219 0.89 KDM4E (0.43) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL17015338 0.89 KDM4E (0.35) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL15631987 0.89 KDM4E (0.50) KDM4EATML3MBTL1BIRC5ALDH1A1
SCHEMBL16357581 0.88 KDM4E (0.44) KDM4EATML3MBTL1BIRC5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.